{"transactions":[{"id":2223129,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125914,"kind":"person","name":"D'Alvise Janelle","position":1,"cik":"0001807412","reported_name":"D'Alvise Janelle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2022-06-23T16:33:34.000Z","date":"2022-06-22","kind":"grant","acquired":true,"shares":560000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$1.15 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7727 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 06/22/2022 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":560000,"derivative":{"exercise_price":0.89,"expiration_date":"2032-06-22","underlying":"Class A Common Shares","underlying_shares":560000},"source":{"system":"sec-edgar","filing":"0001171843-22-004514","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807412/000117184322004514/ownership.xml","form_type":"4"}},{"id":2510868,"issuer":{"id":7266,"kind":"organization","name":"Grace Therapeutics, Inc.","symbol":"GRCE"},"owners":[{"id":125914,"kind":"person","name":"D'Alvise Janelle","position":1,"cik":"0001807412","reported_name":"D'Alvise Janelle","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"PRESIDENT & CEO"}}],"security":"Stock Options (Right to Buy)","published_at":"2021-11-16T16:18:06.000Z","date":"2021-11-12","kind":"grant","acquired":true,"shares":655500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Based on conversion of exercise price of C$2.05 into U.S. dollars based on an exchange rate of C$1.00 = US$0.7959 on the date of grant."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"Stock options granted on 11/12/2021 under Acasti Pharma Inc.'s Stock Option Plan and become exercisable evenly and on a quarterly basis over 36 months."}],"balance_after":655500,"derivative":{"exercise_price":1.63,"expiration_date":"2031-11-12","underlying":"Class A Common Shares","underlying_shares":655500},"source":{"system":"sec-edgar","filing":"0001171843-21-008006","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1807412/000117184321008006/ownership.xml","form_type":"4"}}]}